![]() |
市場調查報告書
商品編碼
1481761
全球 HER2 抗體市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測Global HER2 Antibodies Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
預計到 2032 年,全球 HER2 抗體市場需求將從 2023 年的 100.2 億美元達到近 170.7 億美元的市場規模,2024-2032 年研究期間複合年成長率為 6.1%。
HER2 抗體構成了一種用於治療 HER2 陽性乳癌的標靶治療形式,HER2 陽性乳癌是一種乳癌亞型,其特徵是人類表皮生長因子受體 2 (HER2) 蛋白過度表現。這些抗體與癌細胞上的 HER2 受體結合,阻斷其訊號傳導路徑並抑制細胞生長和增殖。透過專門針對 HER2 陽性癌細胞,這些抗體有助於選擇性殺死癌細胞,同時不傷害正常細胞,從而最大限度地減少副作用。 HER2 抗體療法通常與化療或其他標靶療法合併使用,以改善 HER2 陽性乳癌患者的治療結果和存活率。
HER2 陽性乳癌(一種以 HER2 蛋白過度表現為特徵的乳癌亞型)的盛行率不斷上升,正在推動對 HER2 抗體等標靶治療的需求。 HER2 陽性乳癌在全球乳癌病例中佔很大比例,因此需要開發有效的治療方案來改善患者的預後。此外,分子診斷和生物標記測試的進步使醫療保健提供者能夠檢測出可能受益於 HER2 標靶治療的患者,進一步推動市場成長。此外,引入具有改進的功效、安全性和耐受性的新型 HER2 抗體可以擴大 HER2 陽性乳癌患者的治療選擇,從而推動市場成長。
此外,製藥公司、研究機構和醫療機構之間的合作推動了 HER2 抗體開發的創新,從而發現了新的治療標靶和聯合療法。此外,支持使用 HER2 抗體治療乳癌的監管批准和報銷政策正在推動市場擴張和可及性。然而,標靶治療和替代治療方案的進步可能會挑戰未來幾年的市場成長。
研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外,這些工具也對全球 HER2 抗體市場的各個細分市場進行了包容性評估。 HER2 抗體產業的成長和趨勢為本研究提供了整體方法。
HER2 抗體市場報告的這一部分提供了國家和區域層面細分市場的詳細資料,從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。
本節涵蓋區域前景,重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲 HER2 抗體市場當前和未來的需求。此外,該報告重點關注所有主要地區各個應用領域的需求、估計和預測。
該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。 HER2抗體市場的主要參與者包括諾華公司、輝瑞、F. Hoffmann-La Roche Ltd.、Abnova Corporation、InvivoGen、Celltrion Inc.、Biocon、Novus Biologicals。本節包含競爭格局的整體視圖,包括各種策略發展,例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。
如果您有任何客製化要求,請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。
The global demand for HER2 Antibodies Market is presumed to reach the market size of nearly USD 17.07 Billion by 2032 from USD 10.02 Billion in 2023 with a CAGR of 6.1% under the study period 2024-2032.
HER2 antibodies constitute a form of targeted therapy employed in treating HER2-positive breast cancer, a breast cancer subtype characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. These antibodies bind to the HER2 receptors on cancer cells, blocking their signaling pathways and inhibiting cell growth and proliferation. By targeting HER2-positive cancer cells specifically, these antibodies help to selectively kill cancer cells while sparing normal cells, minimizing side effects. HER2 antibody therapies are often used in combination with chemotherapy or other targeted therapies to improve treatment outcomes & survival rates among patients with HER2-positive breast cancer.
The increasing prevalence of HER2-positive breast cancer, a subtype of breast cancer featured by overexpression of the HER2 protein, is driving demand for targeted therapies such as HER2 antibodies. HER2-positive breast cancer accounts for a significant proportion of breast cancer cases globally, necessitating the development of effective treatment options to improve patient outcomes. Additionally, advancements in molecular diagnostics and biomarker testing have enabled healthcare providers to detect patients likely to benefit from HER2-targeted therapies, further driving market growth. Moreover, introducing novel HER2 antibodies with improved efficacy, safety, and tolerability profiles expands treatment options for patients with HER2-positive breast cancer, driving market growth.
Furthermore, collaborations between pharmaceutical companies, research institutions, and healthcare organizations drive innovation in HER2 antibody development, resulting in the discovery of new therapeutic targets and combination therapies. Additionally, regulatory approvals and reimbursement policies supporting the use of HER2 antibodies in treating breast cancer are driving market expansion and accessibility. However, advancements in targeted therapies and alternative treatment options may challenge the market growth in the coming years.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of HER2 Antibodies. The growth and trends of HER2 Antibodies industry provide a holistic approach to this study.
This section of the HER2 Antibodies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the HER2 Antibodies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the HER2 Antibodies market include Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Abnova Corporation, InvivoGen, Celltrion Inc., Biocon, Novus Biologicals. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.